The efficacy and safety of dual oral therapy with daclatasvir and asunaprevir for genotype 1b in Japanese real-life settings.
about
Serial changes in liver stiffness and controlled attenuation parameter following direct-acting antiviral therapy against hepatitis C virus genotype 1b.Real-life prevalence of resistance-associated variants against non-structural protein 5A inhibitors and efficiency of Daclatasvir + Asunaprevir therapy in Korean patients with genotype 1b hepatitis CAssociation between alanine aminotransferase elevation and UGT1A1*6 polymorphisms in daclatasvir and asunaprevir combination therapy for chronic hepatitis C.Systematic review with meta-analysis: effectiveness and tolerability of interferon-free direct-acting antiviral regimens for chronic hepatitis C genotype 1 in routine clinical practice in Asia.Hepatic decompensation during paritaprevir/ritonavir/ombitasvir/dasabuvir treatment for genotype 1b chronic hepatitis C patients with advanced fibrosis and compensated cirrhosis
P2860
The efficacy and safety of dual oral therapy with daclatasvir and asunaprevir for genotype 1b in Japanese real-life settings.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
The efficacy and safety of dua ...... n Japanese real-life settings.
@en
type
label
The efficacy and safety of dua ...... n Japanese real-life settings.
@en
prefLabel
The efficacy and safety of dua ...... n Japanese real-life settings.
@en
P2093
P2860
P356
P1433
P1476
The efficacy and safety of dua ...... n Japanese real-life settings.
@en
P2093
Fumitaka Suzuki
Hiromitsu Kumada
Kenji Ikeda
Mariko Kobayashi
Masahiro Kobayashi
Norio Akuta
Satoshi Saitoh
Shunichiro Fujiyama
Yasuji Arase
Yoshiyuki Suzuki
P2860
P304
P356
10.1111/LIV.13384
P577
2017-02-08T00:00:00Z